Caplin Point Laboratories Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/596hmz5z373ekmxgwycakim5.pdf

Key Takeaways


Steriles & the Injectables Engine

Paarthipan: "Slight dip here and there is likely to be there in any company, and it's more like a bend if not an end."

U.S. Market Entry & Front-End Strategy


LatAm Moat & Business Model

Paarthipan: "If you want to be a numero uno, even if it is a smaller business, you cannot run faster than a person in the form of a giant. You will only have to run in the opposite direction."

Biosimilars & the China Pivot


Facilities, Capex & Automation

Paarthipan: "Be uncomfortable for a year or two to be comfortable for the rest of the years to come."

Cash, Capital Allocation & Acquisitions

Paarthipan: "You know there is saying, people always say 'Top line is vanity, bottom line is sanity, cash is king'. And we keep the cash for future acquisition."

Guidance & Commitments

CommitmentSpecificsTimeline
U.S. state licensingSubstantially licensed across close to all 50 statesNext 2-3 months
Line 6 qualificationPrefilled syringe and cartridge line fully qualifiedNext 1 month
Caplin One Labs injectablesCommissioning completed, then EU audit and U.S. FDA inspection10-12 months for commissioning
API facilities completionAPI facility in Vizag and Onco API2025
Mexico own-warehouse entryOnce 25-30 products registered, start own warehouse and private market~2 years from now
Biological products businessFill-finish model generating good business irrespective of market size2-3 years from now[7-8]
Caplin Onco profitabilityBecome profitable~6 quarters
U.S. own-label salesSome sales from own label by end of FY25, meaningful laterFY25 exit / FY26 onwards
Residual capex~₹250-300 crores across OSD, API, injectable equipment, CP-1 linesNext couple of years
OSD facility for U.S.Construction start on second facility on purchased land~6 months from now

Key Metrics

MetricQ4 FY24
Revenue growth15.5% YoY
PAT growth22.4% YoY
PAT margin26.19%, above guided range of 24.5% to 25%
Contribution margin increase~3% YoY, overall contribution increase of ~₹166 cr
EBITDA contribution from revenue increase₹122 cr of the ₹176 cr increase in contribution and other income flowed directly to EBITDA
Cash and cash equivalents~₹910 cr as of March 2024
Cash flow from operations₹318 cr, ~60% of PBT
Caplin Steriles revenue~₹313 cr for FY24, over 50% growth YoY
Caplin Steriles EBITDA₹61.2 cr for FY24
Caplin Steriles PAT₹18.7 cr for FY24
Caplin Steriles revenue split~75% product revenue, 25% milestones and profit share
Caplin Steriles output~2.7 crore vials in FY24, up from 1.6 crore vials in FY23
Approved ANDAs21 approved, 14 under review
U.S. state licenses obtained27 out of 50
Products under active development35 to be filed over next two to three years
Softgel capacity utilization90% to 95% of enhanced capacity
Caplin Onco loss for FY24₹2.82 cr, operations commenced 15 March 2024
Pending CAPEX~₹250–300 cr over next couple of years
Capital work in progress₹116.6 cr
Product registrations from India4,485
Product registrations from China275
China-sourced business mix20% of total, down from 60% historically
LatAm concentration75%–80% of total business from six smaller geographies